Communiqués Ono Pharmaceutical Co., Ltd.

Actions

4528

JP3197600004

Produits pharmaceutiques

Temps Différé Japan Exchange 02:21:19 06/10/2026			Varia. 5j.	Varia. 1 janv.
2 268,00 ^JPY	-0,46%		-2,79%	+4,42%

02/09	Ono Pharmaceutical Co., Ltd. conclut un partenariat de découverte de médicaments avec Aitia, Inc	CI
31/07	Ono Pharmaceutical : le bénéfice bondit de 37 % au premier trimestre fiscal	MT

Communiqués

01/10	Ono Pharmaceutical : Venture Investment Relocates to Cambridge, Massachusetts— Accelerating Open Innovation and Maximizing Strategic Returns —	PU
16/09	Ono Pharmaceutical : Received Manufacturing and Marketing Approval in Japan for XCOPRI® Tablets for the Treatment of Patients with Partial-onset Seizures, With or Without Secondary Generalized Seizures	PU
20/08	Ono Pharmaceutical - OPDIVO Intravenous Infusion Approved in Taiwan for the Treatment of Resectable Non-Small Cell Lung Cancer with Neoadjuvant OPDIVO in Combination with Chemotherapy	AQ
19/08	Ono Pharmaceutical : OPDIVO® Intravenous Infusion Approved in Taiwan for the Treatment of Resectable Non-Small Cell Lung Cancer with Neoadjuvant OPDIVO in Combination with Chemotherapy Followed by Surgery and Adjuvant Single-Agent OPDIVO	PU
17/08	Ono Pharmaceutical : Continues to be Selected for ESG Investment Indexes Adopted by GPIF	PU
07/08	Ono Pharma Enters into a Drug Discovery Partnership with Mediar Therapeutics to Create Novel Antibody Therapeutics for Fibro-inflammatory Diseases	AQ
04/08	Ono Pharmaceutical : OPDIVO® Intravenous Infusion Approved in South Korea for the Treatment of Resectable Non-Small Cell Lung Cancer with Neoadjuvant OPDIVO in Combination with Chemotherapy Followed by Surgery and Adjuvant Single-Agent OPDIVO	PU
10/07	Ono Pharmaceutical : Notice concerning Completion of Disposal of Treasury Shares as Tenure-based Restricted Stock Compensation and Performance-linked Restricted Stock Compensation	PU
18/06	Ono Pharmaceutical : Notice of Disposal of Treasury Shares as Tenure-based Restricted Stock Compensation and Performance-linked Restricted Stock Compensation	PU
11/06	Ono Pharmaceutical : Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement of Malignant Lymphoma in Patients with Inadequate Response to Existing Therapies or in Whom Such Therapies Are Not Appropriate	PU
11/06	Ono Pharmaceutical : Pharma Submits a Supplemental Application in Japan to Expand the Use of OPDIVO for the Treatment of Unresectable Anaplastic Thyroid Cancer	PU
02/06	Ono Pharmaceutical : Pharma Announces Oral Presentation of New Data from Phase 2 Clinical Study of -4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting	PU
28/05	Ono Pharmaceutical : Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of -2808 (S1P5 Receptor Agonist) in Multiple System Atrophy at the 7th World Parkinson Congress (WPC)	PU
22/04	Ono Pharmaceutical : Pharma Announces Upcoming Presentations at the ASCO 2026 Annual Meeting	PU
11/03	Ono Pharmaceutical : Vertex Announces Positive Week 36 Interim Analysis Results from the Global RAINIER Phase 3 Trial of Povetacicept	PU
05/03	Ono Pharmaceutical : Notice Concerning Disposal of Treasury Shares by Third-Party Allotment	PU
05/03	Ono Pharmaceutical : Notice concerning Introduction of Long-Term Incentive Stock Plan for Employees of Deciphera, the U.S. Subsidiary	PU
04/03	Sinopia Biosciences Announces Target Discovery Collaboration with Ono Pharmaceutical for Rare Metabolic Disorders	AQ
02/03	Ono Pharmaceutical : Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment to Daito Pharmaceutical Co., Ltd.	PU
02/03	Ono Pharmaceutical : Announcement on Changes of the Board of Directors and Corporate Officers	PU
27/02	Ono Pharmaceutical : Announcement concerning the Transfer of Distribution, Sales and Termination of Co-promotion for SGLT2 Inhibitor “Forxiga® 5 mg, 10 mg Tablets’’ in Japan	PU
24/02	Ono Pharmaceutical : Opdivo® (nivolumab) Intravenous Infusion Approved in South Korea in Combination with Yervoy® (ipilimumab) for the Treatment of Adult Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer	PU
16/02	Ono Pharmaceutical : Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL	PU
15/01	Ono Pharmaceutical - Opdivo Intravenous Infusion Approved in Taiwan in Combination with Yervoy for the Treatment of Adult Patients	AQ
15/01	Ono Shares Replay Information for 44th Annual J.P. Morgan Healthcare Conference Presentation	BU